DEPO is off 60% pre market on this: July 10 (Reuters) - Depomed Inc. (DEPO.O: Quote, Profile, Research) said late-stage trials of Gabapentin GR to treat postherpetic neuralgia did not meet its main goal. http://biz.yahoo.com/ap/070710/depomed_trial.html?.v=1
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.